Skip to main content

MEDIFAST INC Value Stock - Dividend - Research Selection

Medifast inc

ISIN: US58470H1014 , WKN: 889384

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why Medifast's $15 Cash Per Share Makes It A Strong Buy

2026-05-13
Cost-cutting initiatives, asset sales, and a positive operating cash flow position Medifast for potential profitability by Q4 2026. Read why MED is a Strong Buy.

Medifast: Worth Putting On A Watchlist

2026-05-12
Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. See why MED stock is a Hold.

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

2026-05-05
MED beats first-quarter estimates despite steep revenue declines, while stronger coach productivity and a new product launch support recovery hopes.

Hims & Hers Expands DTC Platform to Broaden Access to Personal Care

2026-05-05
HIMS broadens its DTC platform with GLP-1 access, a new Benefits hub and global expansion to broaden convenient, personalized care.

Medifast Q1 Earnings Call Highlights

2026-05-05
Medifast (NYSE:MED) reported first-quarter 2026 results that management characterized as an early step toward stabilizing the business as it pivots from traditional weight loss to a broader metabolic health positioning amid continued disruption from GLP-1 drug adoption. On the company’s earnings ca

Medifast, Inc. Q1 2026 Earnings Call Summary

2026-05-05
Moby summary of Medifast, Inc.'s Q1 2026 earnings call

Medifast (MED) Q1 2026 Earnings Transcript

2026-05-04
Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, and other similar expressions generally identify forward-looking statements. Actual results could differ materially from those projected in any forward-looking statements.

Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates

2026-05-04
Medifast (MED) delivered earnings and revenue surprises of +65.46% and +3.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Medifast (NYSE:MED) Q1 Loss Narrower Than Feared as Coach Productivity Improves

2026-05-04
Medifast Q1 loss of $0.19/share beat estimates, with revenue of $76M topping forecasts. Coach productivity improved 19.2% YoY, though active coaches fell 44.9%. Full-year guidance suggests deeper losses ahead.

Medifast (NYSE:MED) Delivers Impressive Q1 CY2026

2026-05-04
Wellness company Medifast (NYSE:MED) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 34.3% year on year to $76.04 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $70 million was less impressive, coming in 6.3% below expectations. Its GAAP loss of $0.19 per share was 63.5% above analysts’ consensus estimates.